Join Growin Stock Community!

巨生醫6827.TW Overview

TW StockBiotech. & Medical
(No presentation for 6827)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

巨生醫（6827）Overall Performance

巨生醫（6827）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

巨生醫（6827） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

巨生醫（6827）Key Information

巨生醫（6827）Profile

MegaPro Biomedical Co., Ltd, a biotech company, focuses on the development of nano drugs. It also develops MPB-1523, an IOP injection that is in Phase II clinical trial for use in the treatment of hepatocellular carcinoma; and MPB-1514, an iron injection that is in Phase II clinical trial for use in the treatment of iron deficiency anemia, as well as MPB-1734, an anti-cancer drug that is in preclinical trial for the treatment of malignant tumor. The company was founded in 2014 and is based in Zhubei, Taiwan.

巨生醫（6827）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.73
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
28669.99
PB Ratio
6.90
Price-to-FCF
13.12
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-925153.13%
Revenue Growth (YoY)
-99.57%
Profit Growth (YoY)
-99.57%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.73
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
28669.99
PB Ratio
6.90
Price-to-FCF
13.12
Gross Margin
100.00%
Net Margin
-925153.13%
Revenue Growth (YoY)
-99.57%
Profit Growth (YoY)
-99.57%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
default symbol

6827

巨生醫

11.55D

0.00%

(0.00)

  • When is 6827's latest earnings report released?

    The most recent financial report for 巨生醫 (6827) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6827's short-term business performance and financial health. For the latest updates on 6827's earnings releases, visit this page regularly.

  • How is 6827's revenue growth?

    In the latest financial report, 巨生醫 (6827) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6827 have?

    At the end of the period, 巨生醫 (6827) held Total Cash and Cash Equivalents of 62.52M, accounting for 0.39 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is 6827's EPS continuing to grow?

    According to the past four quarterly reports, 巨生醫 (6827)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -1.06. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.